Leveraging Synthetic Biology to Create Better Treatments For Lynch Syndrome and FAP
Updated: May 18, 2020
Engineered Nissle bacteria has been previously tested pre-clinically and in Phase 2 clinical trails. It was well tolerated and elucidated desired biologic effects. This is why we are engineering Nissle bacteria for human clinical evaluation in a variety of rare diseases.
In Clinical Trails Engineered Nissle Was Shown to Well Tolerated and Clear The Gut